Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Biomarkers Predict Brain Tumor's Response To Therapy
- Contamination Forces Recall of Hand Sanitizers
- Safety And Cognitive Stability Are Key Findings In Phase IIA Trial Of New Alzheimer's Disease Treatment From Humanetics Corporation
- Risk Of HIV Transmission Not Reduced By Herpes Medication
- Pharmacy Bodies Work Together To Promote The Integration Of Pharmacy Within Lord Darzi's Primary & Community Care Strategy
- What's The Skinny On Fat Removal? Dermatologists Believe Emerging Non-Invasive Technologies Shaping Up To Be The Next Big Thing
- Total Laparoscopic Aortic Surgery Is Feasible, Shows Satisfactory Results
- Lancet Publishes 48 Week Phase III Data For 'Isentress'® (Raltegravir) In Previously Untreated (Treatment-Naïve) HIV-Infected Patients
- Research To Be Presented At The 2009 American Association Of Pharmaceutical Scientists Annual Meeting And Exposition
- Limited-Option HIV Drug Approved for Expanded Use
Hatwig Receives American Society of Health-System Pharmacists Award Of Excellence
Posted by: admin in Pharmacy Drugs on September 24th, 2009
The American Society of Health-System Pharmacists (ASHP) today honored Christopher A. Hatwig, M.S., FASHP, with the ASHP Board of Directors Award of Excellence for his work to help safety net hospitals provide safe and cost-effective drug therapy to low-income and uninsured patients. Hatwig, vice president of Apexus in Irving, Texas, received the award during ASHP’s Summer Meeting in Rosemont, Ill.
Apexus is responsible for managing the Health Resources and Services Administration’s (HRSA) 340B Prime Vendor Program. Mr. Hatwig works closely with HRSA’s Office of Pharmacy Affairs and the Pharmacy Services Support Center in Washington, D.C. to educate all stakeholders, and to improve the integrity and value of the 340B Drug Pricing Program for the nation’s safety-net providers. Under his leadership, the program generated savings of over $24 million or an average savings of 16 percent below the federal 340B ceiling price on its contracted products in 2008. Apexus is a wholly owned non-profit subsidiary of Provista Inc.
Before joining Apexus, Hatwig was the director of ambulatory pharmacy services and value analysis programs at Parkland Health & Hospital System in Dallas where he practiced for 13 years. At Parkland he managed one of the nation’s largest and more progressive ambulatory pharmacy programs serving the low-income and uninsured. He was responsible for managing Parkland’s network of ambulatory pharmacies, which processed over two million prescriptions annually and operated with a drug expense budget of $65 million.
“Mr. Hatwig’s work with the 340B program ensures that the most vulnerable patients in our country have access to the critical medications that they need and the expertise of pharmacists to guide their use,” said Kevin J. Colgan, M.A., FASHP. “We are pleased to recognize his efforts with the Award of Excellence.”
Hatwig has made numerous presentations on the 340B drug pricing program, innovative ambulatory pharmacy services, and drug cost containment strategies. He has served as chair of the ASHP Council on Administrative Affairs and is a reviewer for the American Journal of Health-System Pharmacy. He is also a member of the Texas Society of Health-System Pharmacists and the Academy of Managed Care Pharmacy.
Mr. Hatwig received his bachelor’s degree in pharmacy from the University of Arkansas and completed residencies in hospital pharmacy and hospital pharmacy administration at the University of Wisconsin, where he also received a master’s degree in hospital pharmacy.
Source
American Society of Health-System Pharmacists